ClinTec International Expands Further in MENA Region with Proposed Opening of Istanbul Office
News May 22, 2013
ClinTec International, a global CRO with a presence in over 40 countries worldwide, today announced its intention to formally open an office in Istanbul, Turkey. The office will not only provide ClinTec’s global team with access to a new patient population, but will also further consolidate the British CRO’s presence in the Middle East and North Africa (MENA) region. The office adds to the company’s current MENA region offices based in Cairo, Egypt, Dubai Health Care City, UAE, and Beirut, Lebanon.
Speaking at the announcement of ClinTec’s new office, the company’s founder and CEO, Dr Rabinder Buttar commented; “The launch of this new office in Turkey confirms ClinTec International’s reputation as a truly global provider of quality assured clinical research services. It also reflects the growing significance of Turkey- and the wider MENA region- to the global clinical research market. We are delighted to be at the forefront of developing expertise in Turkey and the MENA region as a whole.”
The announcement ClinTec’s new Turkey office coincides with the company sponsoring the Partnerships in Clinical Trials Russia-CIS & MENA-Turkey conference held in Istanbul on 22-23rd May 2013. The conference aims to explore the challenges and opportunities facing companies when conducting clinical trials in the MENA region, and looks for the leading CROs within the region to provide solutions and advice on this complex market. As such, ClinTec’s Executive Vice-President- Global Clinical Development, Bindhya Cariappa, will be delivering a speech on Rare Disease Trials in the MENA region.
“Our sponsorship of the Partnerships in Clinical Trials Russia-CIS & MENA-Turkey Conference, coupled with the opening of the Turkey office, further emphasises our belief that ClinTec’s experienced local management team can easily negotiate the fast-moving and constantly evolving trial environment within the region,” added Dr Buttar.
Arsenic Trioxide Could Extend Lives of Patients with Aggressive Brain CancerNews
Arsenic trioxide could be a powerful therapy that could extend the lives of certain glioblastoma patients by as much as three to four times the median expectation.READ MORE
XenoGesis and Juniper Pharma Services Strengthen AllianceNews
Campanies extend strategic alliance in early drug development services.READ MORE
Quotient Clinical Signs Cocrystal Agreement with NuformixNews
Partnership to evaluate cocrystal formulations using translational pharmaceutics.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018